OpenPayer

This revision, effective 6/15/2026, clarifies and consolidates coverage criteria related to surgical and procedural interventions for obstructive sleep apnea (OSA) across age groups. The document explicitly defines medical necessity for drug-induced sleep endoscopy (DISE), uvulopalatopharyngoplasty (UPPP), multi-level or stepwise surgery (MLS), maxillomandibular advancement (MMA), and FDA-approved implantable upper airway hypoglossal nerve stimulation devices. It also restates that coverage is subject to the terms of the member's specific benefit plan and that delegated vendor guidelines may be used in certain markets.

The revision emphasizes objective thresholds and prior therapy considerations—most notably polysomnography AHI cutoffs, PAP treatment failure or intolerance definitions, and age/BMI/AHI criteria for specific implantable hypoglossal nerve stimulation systems. The document also distinguishes indications by patient population (adult, adolescent with Down syndrome, pediatric) and by whether procedures are performed as stand-alone or in combination.

The policy defines DISE as medically necessary in adults when either persistent OSA exists after PAP has failed (AHI > 15) or PAP intolerance/unwillingness is documented, or when OSA persists after prior upper airway surgery. For adolescents (ages 13–18) with Down syndrome, DISE is medically necessary specifically to evaluate candidacy for an FDA-approved implantable hypoglossal nerve stimulation device. In children, DISE is medically necessary for evaluation of persistent post-surgical OSA or suspected OSA when performed in conjunction with other airway surgeries (e.g., tonsillectomy/adenoidectomy).

These criteria anchor DISE coverage to concrete scenarios: documented PAP failure/intolerance, post-operative persistence of OSA, or use in a pediatric surgical context. The policy links DISE coverage tightly to diagnostic or procedural decision-making for upper airway surgical management rather than routine evaluation.

Surgical airway procedures are covered with defined prerequisites. UPPP is medically necessary for adult OSA when there is documented retropalatal narrowing/collapse and PAP treatment failure, intolerance, or unwillingness; the policy also notes consideration of a mandibular repositioning appliance (MRA) or tongue-retaining appliance for adults. Uvulectomy as a standalone treatment for OSA is explicitly considered not medically necessary, although the procedure for other non-OSA indications is outside the scope of this policy.

For multi-level or stepwise surgeries (e.g., UPPP, genioglossus advancement and hyoid myotomy, MMO), medical necessity requires multilevel upper airway narrowing and the same PAP-related prerequisites; in adults, an MRA or tongue-retaining appliance must have been considered and found ineffective or undesirable. Maxillomandibular advancement is limited to severe OSA when PAP failure/intolerance is present, conservative oral appliance options have been considered in adults, and the individual has craniofacial disproportion or deformities.

The policy sets explicit medical necessity criteria for FDA‑approved implantable upper airway hypoglossal nerve stimulation devices with device-specific parameters. For the Inspire Upper Airway Stimulation System (Inspire Medical Systems), adults must be ≥ 18 years, have AHI on PSG ≥ 15 and ≤ 100 events/hour, and BMI ≤ 40. For the Genio ® System 2.1 (Nyxoah S.A.), adults must be ≥ 22 years, have AHI on PSG ≥ 15 and ≤ 65 events/hour, and BMI ≤ 32. Across devices, additional requirements include central + mixed apneas ≤ 25% of total AHI, absence of complete concentric collapse at the soft palate on DISE, and documented PAP failure, intolerance, or unwillingness.

For pediatric individuals with Down syndrome, an FDA-approved implantable hypoglossal stimulation device is considered medically necessary when age, AHI, and BMI criteria are met, there is no complete concentric collapse at the soft palate, adenotonsillectomy is contraindicated or ineffective, PAP therapy has failed or is not tolerable despite compliance efforts, and all other alternative/adjunct therapies have been considered.

The policy reiterates the central role of positive airway pressure (PAP) therapy status in coverage determinations. Across surgical and device-based interventions, medical necessity hinges on documentation of PAP treatment failure (inability to eliminate OSA defined by AHI thresholds), PAP intolerance (inability to use PAP > 4 hours per night, 5 nights per week), or explicit patient unwillingness (e.g., returning the PAP system after attempting use). These PAP-related definitions are applied consistently across DISE, UPPP, MLS, MMA, and implantable stimulation device criteria.

Additionally, the policy emphasizes that coverage varies by plan and the customer's benefit document supersedes the Coverage Policy if conflicts exist. Coding and billing must use appropriate codes as of the service date; services billed without covered codes under the applicable Coverage Policy will be denied as not covered. The policy also notes that it does not address uvulectomy for non-OSA indications.